Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 18OTHER 4NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × brivanib × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡